Anti-Mouse CD155 (PVR) [Clone 4.24.1] — Purified in vivo PLATINUM™ Functional Grade

Common In Vivo Applications of Clone 4.24.1 in Mice

Clone 4.24.1 is a rat monoclonal antibody that specifically recognizes mouse CD155 (also known as the poliovirus receptor, PVR). CD155 is a transmembrane glycoprotein involved in cell adhesion and immune regulation, expressed on various cell types including vascular endothelial cells, thymocytes, and hematopoietic cells.

Functional Blockade of CD155 Pathways
The primary in vivo application of clone 4.24.1 is the functional blockade or modulation of CD155-mediated signaling pathways in living mice. By administering this antibody, researchers can interfere with the interaction between CD155 and its ligands (such as CD226 and CD96), which are critical for the cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). This approach allows investigators to dissect the role of CD155 in immune cell engagement, tumor immunity, and receptor-ligand interactions within the intact organism.

Tumor Immunity and Tumor Burden Studies
Clone 4.24.1 has been used to monitor tumor burden in mice, particularly in the context of evaluating how CD155 blockade affects tumor growth and immune responses. Since CD155 is often overexpressed on tumor cells and can suppress anti-tumor immunity, blocking its function with this antibody can reveal its contribution to immune evasion and may help identify potential therapeutic strategies.

Modeling Immune Disorders
While not explicitly detailed in the provided sources, given CD155’s role in immune regulation, clone 4.24.1 could also be applied to model immune-related disorders (e.g., graft-versus-host disease, GVHD). By modulating CD155 signaling, researchers can explore its impact on immune tolerance, inflammation, and tissue damage in vivo.

Key Features of Clone 4.24.1 for In Vivo Use

• Specificity: The antibody binds a unique epitope on mouse CD155, ensuring targeted modulation of CD155-specific pathways.
• Functional Grade: The antibody is produced under conditions that minimize endotoxin and aggregation, making it suitable for in vivo injection.
• Manufacturing: Produced in animal-free facilities using protein-free cell culture techniques, reducing the risk of contamination.
• Storage: Should be stored sterile and aliquoted for long-term use to maintain activity.

Summary Table

Clone 4.24.1 is a valuable tool for in vivo research focused on the immunological functions of CD155 in mice, particularly in tumor immunology and immune regulation studies.

Commonly Used Antibodies and Proteins Paired with 4.24.1 (4-1BB Agonist)

The antibody clone 4.24.1 is known as a 4-1BB (CD137) agonist, primarily used in immunotherapy research, particularly in the context of activating T cells for cancer treatment. Several other antibodies and proteins are frequently used in combination with 4.24.1 in the literature, aiming to achieve synergistic effects, enhance specificity, or counteract immunosuppressive mechanisms in the tumor microenvironment.

Key Pairings

Brief Explanations

• Her2 Targeting: By co-targeting Her2, researchers aim to focus the immune-stimulatory effects of 4.24.1 on tumors that express this antigen, potentially increasing efficacy and reducing systemic toxicity.
• PD-L1 Blockade: Combining 4.24.1 with PD-L1 inhibitors (e.g., anti-PD-L1 antibodies) is designed to relieve T cell suppression in the tumor, allowing 4-1BB agonism to more effectively activate anti-tumor T cell responses.
• FAP Targeting: Co-targeting FAP localizes the immune response to the tumor stroma, aiming to reduce off-tumor effects and enhance the specificity of immunotherapy.

These combinations highlight a strategic approach in immunotherapy research—using 4.24.1 as a T cell co-stimulator alongside antibodies or proteins that either enhance tumor targeting or counteract immunosuppressive signals. While this table summarizes the most commonly reported pairings, the literature continues to explore additional combinations based on tumor type and the immune context.

Clone 4.24.1 refers to a monoclonal antibody targeting mouse CD155 (also known as PVR). It is commonly utilized in in vivo mouse studies to block or investigate the function of the CD155 molecule on mouse cells.

Key findings from scientific literature citing clone 4.24.1 include:

• Functional Targeting: Clone 4.24.1 is regularly cited and used as a tool to functionally block or study CD155 during mouse immunological experiments.
• Immunotherapy and Tumor Immunology: CD155 is an immune checkpoint molecule. Clone 4.24.1 is cited in studies exploring immune regulation, particularly the inhibition or activation of immune cells through pathways involving CD155, especially in cancer immunotherapy research.
• Preclinical Research: Publications often cite this clone for preclinical mouse models to assess the biological relevance of CD155 interactions, either in tumor growth, immune cell infiltration, or response to immune checkpoint blockade.

Due to the specificity and widespread use of this antibody in mouse CD155-related research, clone 4.24.1 is a well-established reagent for experiments that require selective targeting or blockade of the CD155 protein in murine systems.

No detailed citation analysis (such as citation context, methodological impact, or publication trends) of clone 4.24.1 itself appears in the provided search results beyond its utility as a research tool. If you require a more exhaustive breakdown of its citation history or bibliometric data, a database search through PubMed, Web of Science, or Google Scholar using terms like "clone 4.24.1 CD155" would yield publication-specific insights.

No detailed, peer-reviewed dosing regimen data for clone 4.24.1 across mouse models is available in the provided search results; this clone is less commonly used than well-characterized antibodies like GK1.5 (anti-CD4), 2.43 (anti-CD8), or 9H10/9D9 (anti-CTLA-4), for which standardized dose ranges and schedules exist.

Key Points:

• No direct referencing: Reputable antibody supplier and database entries for clone 4.24.1 do not specify recommended dose, frequency, or administration route in vivo.

• General In Vivo Antibody Dosing Guidelines: For functionally similar antibodies targeting immune cell surface markers in mouse models, commonly cited dosing regimens are:

  • Dose: 100–250 μg per mouse per injection
  • Route: Intraperitoneal (i.p.) injection most frequently used
  • Frequency: Every 2–3 days, or 2–3 times per week, depending on study aims and immune cell turnover rates.

• Variation by Mouse Strain and Model: Dosing regimens (amount, schedule, and duration) can vary based on:

  • Mouse strain (e.g., C57BL/6, BALB/c)
  • Tumor vs. autoimmune or infection models
  • Experimental endpoints (cell depletion kinetics, immune activation, or functional blockade).

• Best Practice: In the absence of published dosing curves for clone 4.24.1, dosing should follow manufacturer technical datasheets, published literature for similar functional clones, and pilot titration studies, with monitoring for desired target engagement and toxicity.

Summary Table for Common Antibody Dosing in Mouse Models (for context):

If you require clone 4.24.1-specific data, consult the antibody supplier's technical support or primary literature where the clone was originally characterized or used in vivo. Inferences about dosing should be made with caution and justified by pilot experiments or side-by-side comparisons with established clones.